643 unknown. 643 Phase 2, 210 Phase 1, 32 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 643 | Unknown 643 |
| Phase 1 | 210 | Unknown 210 |
| Phase 3 | 32 | Unknown 32 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL Polatuzumab vedotin, Rituximab, Orelabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Affiliated Hospital of Nantong University | 30 | 2024-08-01 | 2025-02-04 |
| RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. Thiotepa - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Xianmin Song, MD | 50 | 2024-07-15 | 2024-08-01 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma CMOEP - Peripheral T Cell Lymphoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 115 | 2024-06-01 | 2024-05-29 |
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 10 | 2024-04-30 | 2024-03-06 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma CM313 injection - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Keymed Biosciences Co.Ltd | 120 | 2024-02-28 | 2023-11-13 |
| CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors CD19&CD20 bispecific CAR-T cells - B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-01-14 | 2024-07-16 |
| A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma KQ-2003 CAR T-cells - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | 29 | 2024-01-11 | 2024-01-25 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma Obinutuzumab Combined With Bendamustine - B Cell Lymphoma | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 134 | 2023-11-30 | 2024-05-16 |
| Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Unknown | Stichting European Myeloma Network | 200 | 2023-11-23 | 2024-04-23 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma SHR-A1912; R-Chemo - B-cell Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-11-17 | 2023-12-27 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL ZR2-ICE - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-10-12 | 2024-03-13 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT blinatumomab - Leukemia, Lymphoid | Phase 2 | Unknown | Sichuan University | 68 | 2023-10-01 | 2023-10-10 |
| Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Linperlisib in combined with Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 32 | 2023-09-25 | 2023-10-16 |
Showing 20 of 643. Sign in to see all of them.
Multiple Myeloma (131) · Lymphoma (125) · Lymphoma, Large B-Cell, Diffuse (106) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (87) · Lymphoma, Non-Hodgkin (78) · Recurrence (63) · Hodgkin Disease (57) · Lymphoma, Follicular (57) · Lymphoma, B-Cell (50) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Lymphoma, Mantle-Cell (41) · Burkitt Lymphoma (39) · Leukemia (37) · Lymphoma, T-Cell, Peripheral (35) · Neoplasms, Plasma Cell (27)
Immune System Diseases (641) · Hemic and Lymphatic Diseases (638) · Immunoproliferative Disorders (638) · Neoplasms by Histologic Type (628) · Neoplasms (622) · Lymphatic Diseases (527) · Lymphoma (311) · Hematologic Diseases (282) · Lymphoma, Non-Hodgkin (249) · Cardiovascular Diseases (143) · Vascular Diseases (143) · Hemorrhagic Disorders (142) · Hemostatic Disorders (142) · Paraproteinemias (142)
Cyclophosphamide (95) · Rituximab (76) · Dexamethasone (68) · Etoposide (45) · Lenalidomide (39) · Vincristine (39) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (38) · Doxorubicin (37) · Cytarabine (36) · Bortezomib (33) · Prednisone (33) · fludarabine (27) · Methotrexate (26) · Melphalan (25) · Busulfan (21)
Chinese PLA General Hospital (22) · Ruijin Hospital (15) · Sun Yat-sen University (15) · Fudan University (12) · The First Affiliated Hospital of Soochow University (11) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9) · Institute of Hematology & Blood Diseases Hospital, China (9) · Nanfang Hospital, Southern Medical University (8) · Peking Union Medical College Hospital (8) · Southwest Hospital, China (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Cancer Research UK (6) · Chongqing Precision Biotech Co., Ltd (6) · Samsung Medical Center (6) · Seoul National University Hospital (6)
China (282) · United States (84) · South Korea (43) · Italy (34) · Germany (21) · Spain (21) · United Kingdom (16) · France (15) · Israel (13) · Canada (12) · Russia (10) · Denmark (8) · Poland (8) · Singapore (8) · Mexico (7)
Cheng Qian, PhD (6) · Cheng Qian, MD, PhD (5) · Sanbin Wang, MD (5) · Ye Guo, MD (5) · Arnon Nagler, MD (3) · Evangelos Terpos, Prof (3) · Jun Zhu, MD (3) · Suzin Mayerson, PhD (3) · Umberto Tirelli, MD (3) · Yifan Zhai, MD, PhD (3) · Benedetto Bruno, MD, PhD (2) · David Cunningham, MD FRCP (2) · David G. Savage, MD (2) · Dehui Zou, Dr. (2) · Eucario Leon Rodriguez, M.D. (2)
PMID 34515338, PMID 40135712, PMID 41671463, PMID 28054442, PMID 31039052, PMID 32632956, PMID 40195173, PMID 11675328, PMID 12543862, PMID 15107815, PMID 15189396, PMID 15507947, PMID 15713717, PMID 15842354, PMID 16155013, PMID 16564913, PMID 17134114, PMID 17360989, PMID 17366834, PMID 18094721, PMID 18213528, PMID 18358930, PMID 18824292, PMID 19064724, PMID 1950172, PMID 19720922, PMID 20067838, PMID 20371346, PMID 20530974, PMID 20637084, PMID 20685256, PMID 20686505, PMID 20959411, PMID 21220611, PMID 21374750, PMID 21390126, PMID 21486866, PMID 21525172, PMID 21796119, PMID 21846410, PMID 21911830, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22080169, PMID 22086414, PMID 22179954, PMID 22265847, PMID 22323480, PMID 22331940
2015 (4), P30CA060553 (4), 2009 (2), 2014 (2), 2017 (2), 2018 (2), 2019 (2), P30CA138292 (2), 2004 (1), 2005 (1), 2016 (1), P30CA015083 (1), P30CA022453 (1), R44CA192576 (1), R44DA049616 (1)